TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03655145

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Haplo donor stem cell transplantation
Description: The algorithm for selection of haploidentical donor has been defined by the french society for stem cell transplantation The stem cell source will be bone marrow for haploidentical transplantation.The bone marrow collection is carried out according to the practice of each centre with a minimal target dose of 3x108 TNC/kg.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HLA 10/10 MUD stem cell transplantation
Description: HLA 10/10 matched unrelated donor myeloablative transplantation
Study: NCT04451785

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: blood sample
Description: 6 tubes of 4 milliliters (ml) maximum (total: 24 ml) will be sampled for the measurements of the different biological markers. In case of the genetic mutation is already known, only 5 tubes will be collected (total: 20 ml).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample
Description: 6 tubes of 4 milliliters (ml) maximum (total: 24 ml) will be sampled for the measurements of the different biological markers. In case of the genetic mutation is already known, only 5 tubes will be collected (total: 20 ml).

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Pulse wave velocity
Description: Non-invasive measurement of pulse wave velocity between the carotid and femoral arteries with piezo-electric sensors.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pulse wave velocity
Description: Non-invasive measurement of pulse wave velocity between the carotid and femoral arteries with piezo-electric sensors.
Study: NCT00994552

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pressure support ventilation
Description: Pressure support ventilation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pressure control ventilation
Description: Pressure control ventilation
Study: NCT03701958

Intervention type: DEVICE
Group type: OTHER
Intervention: Exalt Model D Single-Use Duodenoscope
Description: Subjects will have a clinically indicated per standard of care ERCP procedure performed with the Exalt single use duodenoscope study device.
Study: NCT02636699

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Viaskin Peanut 250mcg
Description: Peanut extract cutaneous patch

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cutaneous patch containing an inactive deposit manufactured to mimic peanut extract
Study: NCT02656017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Monitoring of tolerability and symptoms.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Monitoring of tolerability and symptoms.
Study: NCT00841841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dipyrone and acetaminophen
Description: The patients were randomly assigned to 2 groups of 15 patients, according to the drug prescribed as postoperative medication: Group I: dipyrone 500 mg every 6 hours (4 males, 11 females, mean age = 25.2 years) and Group II: paracetamol 750 mg every 6 hours (3 males, 12 females, mean age = 26.8 years)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dipyrone and acetaminophen
Description: The patients were randomly assigned to 2 groups of 15 patients, according to the drug prescribed as postoperative medication: Group I: dipyrone 500 mg every 6 hours (4 males, 11 females, mean age = 25.2 years) and Group II: paracetamol 750 mg every 6 hours (3 males, 12 females, mean age = 26.8 years)
Study: NCT00259909

Intervention type: OTHER
Intervention: GSK questionnaire
Description: GSK questionnaire will demonstrate the validity, reliability and responsiveness as a tool for measuring subject-reported outcomes during an acute exacerbation of chronic obstructive pulmonary disease.

Intervention type: OTHER
Intervention: St. George's Respiratory Questionnaire
Description: The SGRQ is a 50-item questionnaire with 76 weighted responses. It provides a Total score and three component scores: Symptoms (distress caused by respiratory symptoms), Activity (physical activities that cause or are limited by breathlessness), and Impacts (social and psychological effects of the disease). The Total score and each of the SGRQ sub-scores are scored from 0 to 100 where 0 indicates best and 100 indicates worst health.

Intervention type: OTHER
Intervention: Acute Short Form 12 version 2
Description: The Acute SF-12v2 is a multipurpose short-form questionnaire with only 12 questions with two summary scores, the SF-12 Physical Component Summary (PCS-12) and the SF-12 Mental Component Summary (MCS-12). The scoring range for the PCS-12 and MCS-12 is 0 to 100, with a lower score indicating a poorer level of health

Intervention type: OTHER
Intervention: Global Efficacy questionnaire
Description: Global Efficacy questionnaire will be administered in an electronic form to validate test-retest reliability, responsiveness and minimum important difference (MID)
Study: NCT01828177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDI-320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDI-320 Monad #1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDI-320 Monad #2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Study: NCT01260493

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: integrated health care chain
Description: Geriatric assessment at ED, case manager with multiprofessional team in the community, support for informal caregivers
Study: NCT03200444

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard adhesive 1
Description: This strip consists of a standard hydrocolloid adhesive found in ostomy products

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard adhesive 2
Description: This strip consists of a standard hydrocolloid adhesive found in ostomy products

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard adhesive 3
Description: This strip consists of a standard hydrocolloid adhesive found in ostomy products

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P-4
Description: Newly developed adhesive P-4

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P-15
Description: Newly developed adhesive P-14

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P-16
Description: Newly developed adhesive P-8
Study: NCT02681809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ocriplasmin 0.0625mg
Description: Up to 3 intravitreal injections of ocriplasmin 0.0625mg approximately 1 month apart

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ocriplasmin 0.125mg
Description: Up to 3 intravitreal injections of ocriplasmin 0.125mg approximately 1 month apart

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Description: 3 sham injections approximately 1 month apart. No actual injections. No medication is used.
Study: NCT01961505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical compound tripterygium
Description: Topical compound tripterygium was applied for the pain and swollen joints on non-woven fabric for 1 hour, twice per day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The topical placebo recipe composes viscous agent which matches by the sucrose, and the usage and dosage were the same as the topical compound tripterygium group.
Study: NCT02721940

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Control group
Description: Patients in the control group will be subjected to arthroscopic debridement and microfracture surgery.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mononuclear Cells
Description: In the treatment group, patients will be given 200 μg zoledronic acid and purified bone marrow mononuclear cells will be injected into the necrotic zone, followed by injection of 5-10 mL normal saline. Finally, the holes for core decompression will be sealed with a small amount of bone wax to prevent leakage.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelets
Description: In the treatment group, patients will be given 200 μg zoledronic acid and purified bone marrow mononuclear cells will be injected into the necrotic zone, followed by injection of 5-10 mL normal saline. Finally, the holes for core decompression will be sealed with a small amount of bone wax to prevent leakage.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid
Description: In the treatment group, patients will be given 200 μg zoledronic acid and purified bone marrow mononuclear cells will be injected into the necrotic zone, followed by injection of 5-10 mL normal saline. Finally, the holes for core decompression will be sealed with a small amount of bone wax to prevent leakage.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: In the treatment group, patients will be given 200 μg zoledronic acid and purified bone marrow mononuclear cells will be injected into the necrotic zone, followed by injection of 5-10 mL normal saline. Finally, the holes for core decompression will be sealed with a small amount of bone wax to prevent leakage.
Study: NCT02659163

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mHealth wristband
Description: A wristband containing several sensors worn by participants to collect daily objective patient-generated health behavior data on physical activity, sleep, and screen time

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth wristband
Description: A wristband containing several sensors worn by participants to collect daily objective patient-generated health behavior data on physical activity, sleep, and screen time

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mHealth scale
Description: A wireless scale used by participants to measure and record daily weight.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth scale
Description: A wireless scale used by participants to measure and record daily weight.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EMA
Description: Self-reported information on sugar sweetened beverage consumption collected via mobile messaging

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMA
Description: Self-reported information on sugar sweetened beverage consumption collected via mobile messaging

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mHealth app
Description: A mobile application that houses study data and provides two-way messaging between the study team and study participants.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth app
Description: A mobile application that houses study data and provides two-way messaging between the study team and study participants.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Behavior Feedback
Description: Provide feedback on patient-generated health behaviors data, along with standard of care recommendations, for self-guided

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated closed-loop feedback system
Description: Daily feedback and weekly e-report cards on patient-generated longitudinal health behaviors along with clinical recommendations via mobile messaging
Study: NCT00589225

Intervention type: GENETIC
Intervention: Genetic Analysis
Description: We will draw one tube of blood from your arm to obtain white blood cells. These white blood cells will be used as a source of DNA for genetic testing.
Study: NCT03252769

Intervention type: OTHER
Group type: OTHER
Intervention: Self-sampling
Study: NCT02830737

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional RFA
Description: Radio frequency ablation via an ultrasound-guided electrode needle penetrating into the lesion center

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No-touch RFA
Description: Radio frequency ablation via an ultrasound-guided electrode needle penetrating into the tumor-free zone (within 5mm along the edge of the tumor)
Study: NCT02082496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: S.c. liraglutide 3.0mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: S.c. liraglutide 3.0mg once daily
Study: NCT03784443

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iluvien 0.19 MG Drug Implant
Description: Fluocinolone Acetonide Sustained Release Intravitreal Implant at Baseline Visit

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Ranibizumab Injection [Lucentis]
Description: Monthly PRN intravitreal injections

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab Injection [Lucentis]
Description: Monthly PRN intravitreal injections

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Intravitreal Injection
Description: Sham injection without penetrating needle and without drug delivery at baseline visit.
Study: NCT04836052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega 3 fatty acid
Description: omega-3-oil 2 gm twice daily PO/NGT/OGT for 28 days or ICU discharge or death.
Study: NCT02958995

Intervention type: OTHER
Intervention: No Intervention

Intervention type: OTHER
Intervention: No Intervention
Study: NCT04364477

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: transversus abdominis plane (TAP) block
Description: The transversus abdominis plane (TAP) block is a regional anesthesia technique described in recent years that provides analgesia for the anterior portion of the abdominal wall after abdominal surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transversus abdominis plane (TAP) block
Description: The transversus abdominis plane (TAP) block is a regional anesthesia technique described in recent years that provides analgesia for the anterior portion of the abdominal wall after abdominal surgery.
Study: NCT00168844

Intervention type: DRUG
Group type: OTHER
Intervention: Tiotropium Inhalation Solution

Intervention type: DRUG
Group type: OTHER
Intervention: Tiotropium Inhalation Solution

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Study: NCT03590444

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab 0.5 MG/0.05 ML Intraocular Solution
Description: Focal laser treatment will be performed using argon laser photocoagulation (VISULAS 532s®, Carl Zeiss Meditec) operating at 532nm and Ranibizumab 0.5 MG/0.05 ML Intraocular Solution.~Ranibizumab 0.5 MG/0.05 ML Intraocular Solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab 0.5 MG/0.05 ML Intraocular Solution
Description: Focal laser treatment will be performed using argon laser photocoagulation (VISULAS 532s®, Carl Zeiss Meditec) operating at 532nm and Ranibizumab 0.5 MG/0.05 ML Intraocular Solution.~Ranibizumab 0.5 MG/0.05 ML Intraocular Solution
Study: NCT00591006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenytoin (brand name Dilantin)
Description: Three days prior to imaging, participants will take two capsules containing phenytoin tablets (100 mg) by mouth at 0900 hours and 2100 hours (400 mg/day) for a total of three days with the last dose at 0900 hours on the day of the imaging (7 doses total).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Beginning two days prior to the imaging (the day after initiating the phenytoin or placebo), participants will begin taking 4 tablets containing hydrocortisone (20 mg) or placebo also at 0900 hours and 2100 hours (160 mg/day) with the last dose at 0900 hours on the day of the imaging (5 doses total). The doses were selected to achieve a low therapeutic blood level of phenytoin and stress level of cortisol. Newcomer et al. (1999) used this dose of hydrocortisone in healthy controls. The imaging will be performed at approximately 1300 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants take two capsules of placebo 100 mg at 0900 hours and 2100 hours for a total of 3 days with the last dose at 0900 hours on the day of imaging (7 doses total). Beginning two days prior to the imaging (the day after initiating placebo), participants will being taking 4 tablets containing placebo (20 mg) also at 0900 hours and 2100 hours with the last dose at 0900 hours on the day of the imaging (5 doses total).
Study: NCT01308541

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: arm 1
Description: Bolus Dose: two bolus doses of 15.0 mg/kg (first dose) and 8.0 mg/kg (second dose), 40 minutes apart.~Continuous Infusion Dose: Total dose of 42.0 mg/kg administered over 3 hours at an infusion rate of 0.40 mg/kg/min for 1 hour, followed by 0.20 mg/kg/min for 1 hour, followed by 0.10 mg/kg/min for 1 hour.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LUSEDRA
Description: Mode of administration: intravenous (IV).Continuous Infusion Dose: Total dose of 42.0 mg/kg administered over 3 hours at an infusion rate of 0.40 mg/kg/min for 1 hour, followed by 0.20 mg/kg/min for 1 hour, followed by 0.10 mg/kg/min for 1 hour.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol (arm 3)
Description: Mode of administration: intravenous (IV). A loading dose administered at a constant infusion rate of 0.20 mg/kg/min (0.50 mL/kg/min) for 10 minutes, followed by a constant-rate 2-hour infusion at 0.10 mg/kg/min; total dose infused over 130 minutes is 14.0 mg/kg.
Study: NCT04303455

Intervention type: DIAGNOSTIC_TEST
Intervention: blood sampling
Description: sampling serum renin
Study: NCT02438176

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single trans-septal puncture
Description: The investigators will compare bilateral groin puncture AF ablation and single groin puncture AF ablation with 1:2 randomization.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional bilateral groin puncture
Description: Bilateral groin puncture AF ablation is control procedure exactly same to routine AF ablation with double trans-septal puncture.
Study: NCT04730440

Intervention type: OTHER
Intervention: AD-TAR
Description: Intervention description: 12 sessions in groups of 4 subject, over 6 weeks (2 sessions per week), using a rehabilitation program named Training of Affect Recognition (TAR).

Intervention type: OTHER
Intervention: AD-Cognitive Stimulation
Description: Intervention description: 12 sessions in groups of 4 subject, over 6 weeks (2 sessions per week), using classic cognitive stimulation workshops.
Study: NCT00654667

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, no active drug, take 5 capsules by mouth daily for one month

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resveratrol
Study: NCT03674944

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Weight Loss (BWL) + Emotion Regulation (ER)
Description: The BWL + ER program will teach Dialectical Behavior Therapy (DBT) skills (dialectical abstinence, emotion regulation skills, mindfulness, and distress tolerance) to the adolescent and parent group sessions. Parents are expected to model skill usage and DBT language with their teen to reinforce the skills at home. Adolescents and parents will track emotions and DBT skills used in diary cards which will be provided. Emotion-Focused Parent Training (EFPT) will be provided to the parents at each session to train the parent to support the adolescent in processing emotions, increasing parental emotion self-efficacy, promoting positive parent-adolescent relationships, and reducing the need for dysfunctional emotion regulation behaviors.Behavior coaching will be provided to the adolescent and parent to encourage compliance and review skills after each session (DBT or BWL).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Weight Loss (BWL)
Description: All participants will be instructed to consume an energy restricted diet based on initial body weight. Participants will be instructed to record and self-monitor their food intake. The physical activity component will focus on increasing both lifestyle activity and structured exercise programs. Behavior change recommendations will include: self-monitoring, goal setting, managing high-risk situations, and relapse prevention. Parenting skills will be discussed during parent group sessions which will encourage parents to adopt authoritative parenting styles with regard to eating and exercise behaviors. Parents will also learn about behavioral modification principles, including modeling, reinforcement, and operant conditioning. Behavior coaching will be provided to the adolescent and parent after each session to encourage compliance, discuss completed homework, review habit books to praise efforts and give feedback for areas of improvement.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Weight Loss (BWL)
Description: All participants will be instructed to consume an energy restricted diet based on initial body weight. Participants will be instructed to record and self-monitor their food intake. The physical activity component will focus on increasing both lifestyle activity and structured exercise programs. Behavior change recommendations will include: self-monitoring, goal setting, managing high-risk situations, and relapse prevention. Parenting skills will be discussed during parent group sessions which will encourage parents to adopt authoritative parenting styles with regard to eating and exercise behaviors. Parents will also learn about behavioral modification principles, including modeling, reinforcement, and operant conditioning. Behavior coaching will be provided to the adolescent and parent after each session to encourage compliance, discuss completed homework, review habit books to praise efforts and give feedback for areas of improvement.
Study: NCT02632032

Intervention type: DRUG
Group type: OTHER
Intervention: Insulin
Description: Monitoring insulin therapy of campers based on their usual regimen (one of the following):~* premixed insulin in the morning and evening,~* premixed insulin in the morning, regular insulin in the afternoon and premixed insulin in the evening,~* regular insulin in the morning and afternoon, and premixed insulin in the evening.~Education of campers on different aspects of diabetes care:~* monitoring of blood glucose~* injection of insulin~* adaptation of insulin doses according to blood glucose and during exercise~* correction of hypoglycemia~* dietary advice
Study: NCT00627263

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress reduction treatment (SRT) program
Description: The SRT program is a cognitive behavioral program that consists of 8 group sessions over a period of 10 weeks.
Study: NCT00423930

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Study: NCT04002401

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Axicabtagene Ciloleucel
Description: A single infusion of CAR-transduced autologous T cells administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Administered intravenously